Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score

Date

04 Oct 2023

Session

Cocktail & Poster Display session

Presenters

Jin-Ku Lee

Citation

Annals of Oncology (2023) 8 (suppl_1_S5): 1-55. 10.1016/esmoop/esmoop101646

Authors

J. Lee1, H.J. Kang2, J. Kim3

Author affiliations

  • 1 Seoul National University, 03080 - Seoul/KR
  • 2 Seoul National University (SNU) - Main Campus, 08826 - Seoul/KR
  • 3 SNUBH - Seoul National University Bundang Hospital, 13620 - Seongnam/KR

Resources

This content is available to ESMO members and event participants.

Abstract 14P

Background

Homologous recombination deficiency (HRD) is a clinically-proven indicator of sensitivity against platinum-based chemotherapy and PARP inhibitors in various malignancies, including ovarian cancers. Until now, HRD prediction has been carried out by detecting the deleterious mutations of the BRCA1 or BRCA2 gene or measuring genomic scar, i.e., scarHRD. However, the scarHRD method has limitations in applying tumors without matched germline data. Investigating HRD-specific transcriptomic signatures is one of the tangible approaches to predicting HRD in tumor-only samples. Although several RNA-seq-based HRD prediction algorithms have been developed, they support mainly cohort-wise classification regarding HRD status yet do not provide an equivalent value to scarHRD. The transformation into scarHRD from transcriptomic data would be highly valuable for clinical application and research use.

Methods

Here, we developed an algorithm of transcriptome-based HRD analysis, i.e., expHRD. The prediction model was established using the elastic net in TCGA-pan cancer training set. HRD geneset for applying expHRD calculation using single-sample geneset enrichment analysis was derived by bootstrap technique.

Results

expHRD is a clinically applicable RNA-seq-based HRD prediction platform in tumor-only samples. In clinic, expHRD can provide supportive information for predicting platinum or PARP inhibitor responses by providing predicted scarHRD score. We could extract the expHRD to analyze the inter-cohort evaluation, HRD-associated gene expression profile, mutations, or tumor types in samples without matched germline data, such as cryopreserved or formalin-fixed tissues, cell lines, or organoids.

Conclusions

Developing a targeted transcriptomic panel for calculating expHRD would be a cost-effective approach to linking our platform with the clinic.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.